New hope for kidney cancer patients after immunotherapy fails

NCT ID NCT03945773

Completed Disease control Sponsor: Ipsen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study looked at whether the drug cabozantinib can help people with advanced kidney cancer that got worse after initial treatment with immunotherapy. 127 participants received cabozantinib as a second-line therapy. The main goal was to see how many patients experienced tumor shrinkage. The study is complete and provides information on the drug's effectiveness and safety in this setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

Contacts and locations

Locations

Beatson West of Scotland Cancer Centre

Glasgow, G12 0YN, United Kingdom
CHRU Besançon

Besançon, 25000, France
CHU Strasbourg

Strasbourg, 67091, France
CHU de Nîmes - Institut de Cancérologie du Gard

Nîmes, 30029, France
Caritas Krankenhaus St.Josef Klinik für Urologie

Regensburg, D-93053, Germany
Centre Hospitalier Lyon Sud

Pierre-Bénite, 69495, France
Centre Hospitalier Universitaire Vaudois

Lausanne, 1011, Switzerland
Centre Jean Perrin

Clermont-Ferrand, 63011, France
Centre Léon Bérard

Lyon, 69008, France
Gustave Roussy

Villejuif, 94805, France
Hospital Lucus Augusti

Lugo, 27003, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital de La Santa Creu i Sant Pau

Barcelona, 08041, Spain
Institut Claudius Régaud

Toulouse, 31059, France
Institut Mutualiste Montsouris

Paris, 75014, France
Institut Paoli Calmettes

Marseille, 13009, France
Institut de Cancérologie de Lorraine

Nancy, 54511, France
Institut de Cancérologie de l'Ouest

Saint-Herblain, 44800, France
Kantonsspital St. Gallen

Sankt Gallen, 9007, Switzerland
Klinikum Der Friedrich-Schiller-Universitaet Jena

Jena, D-07747, Germany
Leiden University Medical Center

Leiden, 2300-RC, Netherlands
M.D. Anderson Center Madrid

Madrid, 28033, Spain
Maxima Medisch Centrum

Eindhoven, 5604 DB, Netherlands
Medizinische Hochschule Hannover

Hanover, D-30625, Germany
Mount Vernon Hospital

Northwood, HA6 2RN, United Kingdom
Otto-von-Guericke-Universität University hospital Magdeburg

Magdeburg, D-39120, Germany
Royal Cornwall Hospital (RCH) - Sunrise Centre

Truro, TR1 3LJ, United Kingdom
SALK - Salzburger Landesklinik

Salzburg, A-5020, Austria
The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom
The Netherlands Cancer Institute - Oncology

Amsterdam, 1066 CX, Netherlands
Universitair Medisch Centrum Utrecht

Utrecht, 3584 CX, Netherlands
University Cancer Center Hamburg Eppendorf

Hamburg, d-20246, Germany
University Hospital Carl Gustav Carus Dresden

Dresden, D-1307, Germany
University Hospital Tuebingen

Tübingen, D-72076, Germany
University, Hospital Münster

Münster, D-48149, Germany
Universitätsklinikum Essen

Essen, D-45147, Germany
Universitätsklinikum Schleswig-Holstein

Lübeck, D-23538, Germany
Universitätsmedzin Charité

Berlin, D-10117, Germany
Universitätsspital Bern, Inselspital

Bern, 3010, Switzerland
Western General Hospital - Edinburgh Cancer Centre

Edinburgh, EH4 2XU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.